Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCVELP in Untreated Follicular and Marginal Zone Lymphoma
NCT00772668Phase 2Terminated
- Sponsor
- University of Miami
- Start
- Sep 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by University of Miami. Started Sep 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00772668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772668.